1. A 29-year-old woman with heterozygous familial hypercholesterolemia (HeFH) has been managed with atorvastatin 40 mg daily for three years with excellent LDL-C reduction. She presents to her internist to discuss plans for pregnancy. Her LDL-C is currently 118 mg/dL. Which of the following represents the most appropriate management of her statin therapy during pregnancy?
A) Continue atorvastatin 40 mg daily, as the cardiovascular risk of undertreated HeFH outweighs teratogenic risk during the first trimester only
B) Switch to pravastatin, which is classified as Pregnancy Category B and may be continued throughout gestation
C) Discontinue atorvastatin immediately upon confirmed pregnancy and withhold all statin therapy for the duration of pregnancy and lactation
D) Reduce atorvastatin to 10 mg daily during the first trimester, then discontinue in the second trimester when organogenesis is complete
E) Continue atorvastatin with close fetal monitoring via monthly ultrasound, as teratogenic risk is theoretical rather than established in human studies
ANSWER: C
Rationale:
All statins are absolutely contraindicated in pregnancy and lactation. Statins inhibit HMG-CoA reductase, blocking the mevalonate pathway, which is essential not only for cholesterol synthesis but also for the production of isoprenoids, dolichols, and other intermediates critical to fetal organogenesis, neuronal migration, and cell membrane assembly. Animal studies consistently demonstrate skeletal malformations, CNS defects, and embryolethality; human registry data, while limited by small numbers, show a signal for congenital anomalies consistent with disrupted cholesterol-dependent developmental signaling. The FDA previously classified statins as Category X (known or potential fetal harm where risk outweighs any benefit), and current labeling universally contraindicates use in pregnancy and lactation. In a patient with HeFH, the duration of statin discontinuation — typically 9 months of gestation plus the breastfeeding period — represents an acceptable interruption given that atherosclerotic risk accumulates over decades and short-term LDL-C elevation during pregnancy does not materially alter long-term cardiovascular outcomes. Statin therapy should be restarted promptly after delivery if the patient does not breastfeed, or after cessation of breastfeeding.
Option A: Option B: Option D: Option E:
Option A: Option A is incorrect because the contraindication applies throughout the entire pregnancy, not only the first trimester; organogenesis is not confined to the first trimester, and cholesterol-dependent fetal signaling (including Sonic hedgehog pathway activation) continues well beyond it.
Option B: Option B is incorrect because no statin carries a Pregnancy Category B designation; pravastatin was previously listed as Category X along with all other statins, and the current FDA labeling system no longer uses letter categories but retains an absolute contraindication for all statins in pregnancy regardless of prior category assignments.
Option D: Option D is incorrect because dose reduction does not eliminate teratogenic risk; the mevalonate pathway inhibition that underlies fetal harm is pharmacodynamically present at any therapeutic dose, and the concept of a safe reduced dose during the first trimester is not supported by any regulatory body or guideline.
Option E: Option E is incorrect because the risk is not merely theoretical — animal data are consistently positive for fetal harm, human registry signals exist, and the FDA contraindication is absolute; monthly ultrasound monitoring does not mitigate biochemical disruption of fetal cholesterol-dependent developmental pathways.
2. A 52-year-old Korean man with type 2 diabetes and an LDL-C of 158 mg/dL is being initiated on statin therapy. His physician considers starting rosuvastatin 20 mg daily, which would be a standard starting dose in a non-Asian patient of similar cardiovascular risk. Which of the following best explains why a lower starting dose of rosuvastatin 5–10 mg daily is recommended in this patient?
A) Asian patients exhibit higher rosuvastatin plasma concentrations at equivalent doses due to pharmacokinetic differences, including OATP1B1-mediated hepatic uptake variation and reduced non-renal clearance, resulting in greater systemic exposure and increased myopathy risk
B) Rosuvastatin undergoes extensive CYP2C9 metabolism in Asian patients, producing a hepatotoxic metabolite that accumulates at standard doses and requires dose reduction to prevent transaminase elevation
C) Asian patients have a higher prevalence of the SLCO1B1 521T>C loss-of-function variant than European populations, which reduces hepatic uptake of rosuvastatin and diverts drug to skeletal muscle, directly causing myopathy at standard doses
D) The dose reduction recommendation reflects rosuvastatin's predominantly renal elimination pathway, which is slower in Asian patients due to a higher background prevalence of subclinical diabetic nephropathy
E) Rosuvastatin binds more avidly to plasma proteins in Asian patients, reducing free drug available for hepatic uptake and necessitating lower doses to achieve equivalent LDL-C reduction without toxicity
ANSWER: A
Rationale:
Rosuvastatin pharmacokinetics differ meaningfully in Asian patients compared to White patients of European descent. Clinical pharmacokinetic studies, including those submitted during FDA review, demonstrated that Asian subjects (specifically those of Japanese, Chinese, Korean, Filipino, and Vietnamese ancestry) exhibit approximately two-fold higher rosuvastatin area under the curve (AUC) and peak plasma concentrations (Cmax) at equivalent doses. The mechanism is multifactorial and includes differences in OATP1B1 and OATP1B3 transporter-mediated hepatic uptake, reduced non-renal clearance, and possibly differences in intestinal absorption. Because rosuvastatin exposure is substantially higher at any given dose in Asian patients, the risk of dose-dependent adverse effects — including myopathy — is increased. The FDA-approved rosuvastatin label explicitly states that Asian patients should be started at 5 mg daily, with a maximum dose of 20 mg daily (versus 40 mg in non-Asian patients). This is a pharmacokinetic-based dose adjustment embedded in the product labeling, not a guideline recommendation.
Option B: Option C: Option D: Option E:
Option B: Option B is incorrect because rosuvastatin is minimally metabolized by CYP2C9 (approximately 10% of clearance); it is not a high-CYP2C9-substrate drug and does not produce a hepatotoxic metabolite via this pathway; hepatic metabolism plays a minor role in rosuvastatin disposition compared to transporter-mediated elimination.
Option C: Option C is incorrect in its mechanistic description; while SLCO1B1 521T>C does affect OATP1B1 function, this variant is not more prevalent in Asian populations compared to European populations (it is actually less common in East Asian cohorts), and the primary explanation for the Asian dose recommendation is overall higher systemic exposure due to transporter and clearance differences, not the SLCO1B1 521T>C variant specifically.
Option D: Option D is incorrect because rosuvastatin is eliminated predominantly via feces (biliary/non-renal route accounts for approximately 90% of elimination); renal elimination is a minor pathway, and subclinical diabetic nephropathy does not explain the pharmacokinetic difference observed in Asian patients at normal renal function.
Option E: Option E is incorrect because rosuvastatin is highly protein-bound (approximately 88%) in all populations, and differential protein binding is not the established mechanism for the observed pharmacokinetic difference; the relevant mechanism is transporter-mediated hepatic clearance, not plasma protein binding variation.
3. A 61-year-old man on atorvastatin 40 mg daily presents with a two-week history of bilateral proximal thigh aching and fatigue. He denies recent vigorous exercise, trauma, or febrile illness. His creatine kinase (CK) is measured at 1,840 U/L (upper limit of normal 200 U/L; 9.2× ULN). Renal function is normal. Which of the following is the most appropriate next step in management?
A) Continue atorvastatin at the current dose and recheck CK in four weeks, as values below 10× ULN do not require any change in therapy under current guidelines
B) Reduce atorvastatin to 20 mg daily and recheck CK in two weeks, as dose reduction is the preferred initial response to statin-associated muscle symptoms with CK elevation
C) Switch immediately to pravastatin 40 mg daily, as hydrophilic statins do not penetrate skeletal muscle and will resolve symptoms without interrupting lipid-lowering therapy
D) Add coenzyme Q10 supplementation and continue atorvastatin, as mitochondrial CoQ10 depletion is the confirmed biochemical mechanism of statin myopathy and supplementation corrects the defect
E) Discontinue atorvastatin, allow CK to normalize and symptoms to resolve, then reassess with a rechallenge or alternative statin strategy
ANSWER: E
Rationale:
Symptomatic statin-associated muscle symptoms (SAMS) accompanied by CK elevation above 4× ULN — and certainly at 9.2× ULN as in this case — represent an indication to discontinue statin therapy. The ACC/AHA 2018 Cholesterol Guideline and supporting expert consensus recommend holding the statin when a patient has muscle symptoms with CK elevation, allowing both symptoms and CK to normalize before reassessment. The threshold of 10× ULN is specifically cited as the level at which statin therapy must be stopped regardless of symptoms (frank myositis/rhabdomyolysis risk zone), but symptomatic patients with CK elevation at lower multiples — particularly 4–10× ULN — should also have therapy held given the symptom burden. After normalization, clinicians may rechallenge with the same statin at a lower dose, switch to an alternative statin (lower myopathy risk profile, such as pravastatin or fluvastatin), or switch to a non-statin lipid-lowering agent. Continuing or merely reducing the dose in the setting of active symptomatic myopathy is not appropriate; dose reduction does not reliably or rapidly resolve muscle injury once it has occurred.
Option A: Option B: Option C: Option D:
Option A: Option A is incorrect because it conflates the asymptomatic CK elevation threshold (where continuation may be appropriate if CK remains below 10× ULN and patient is asymptomatic) with the symptomatic SAMS scenario; this patient has active muscle symptoms, which change the clinical calculus and require stopping therapy regardless of the exact CK multiple.
Option B: Option B is incorrect because dose reduction is not the recommended initial response to symptomatic SAMS with CK elevation; the appropriate step is discontinuation, symptom resolution, and CK normalization before any rechallenge; reducing the dose while symptoms are active delays resolution and risks ongoing muscle injury.
Option C: Option C is incorrect because while hydrophilicity does confer a lower muscle penetration and a modestly lower myopathy signal, the switch should occur after discontinuation and symptom resolution, not as an immediate substitution during an active symptomatic episode; furthermore, the claim that hydrophilic statins do not penetrate skeletal muscle is an oversimplification — some uptake does occur.
Option D: Option D is incorrect because coenzyme Q10 supplementation has not been shown in controlled trials to prevent or treat statin-associated myopathy; while mitochondrial CoQ10 depletion has been proposed as a contributing mechanism, it is not the confirmed sole cause, and supplementation is not a guideline-endorsed treatment that permits continuation of statin therapy during active symptomatic SAMS.
4. A 58-year-old woman with hypertension, obesity (BMI 31 kg/m²), and a fasting glucose of 108 mg/dL (impaired fasting glucose) is started on rosuvastatin 20 mg daily for primary cardiovascular prevention. Eighteen months later her fasting glucose is 134 mg/dL and HbA1c is 6.7%, meeting criteria for type 2 diabetes mellitus. Which of the following best characterizes the relationship between her statin use and this new diagnosis?
A) Statin-induced diabetes is caused by direct pancreatic beta-cell cytotoxicity from HMG-CoA reductase inhibition, and the effect is fully reversible upon statin discontinuation in most patients
B) Statins modestly increase the risk of new-onset diabetes, particularly in patients with pre-existing insulin resistance risk factors; the cardiovascular benefit of statin therapy in high-risk patients substantially outweighs this metabolic risk, and statin therapy should be continued with intensified glucose management
C) The association between statin use and new-onset diabetes is a statistical artifact driven by confounding — patients started on statins have higher baseline cardiovascular risk factors that independently predict diabetes, and no causal mechanism has been established
D) Statin-induced diabetes is a class effect limited to lipophilic statins (atorvastatin, simvastatin) due to their direct skeletal muscle glucose transporter (GLUT4) downregulation; switching to a hydrophilic statin eliminates the risk
E) Rosuvastatin carries the highest diabetogenic risk among statins due to its potent HMG-CoA reductase inhibition, and patients with impaired fasting glucose should receive a lower-potency statin to avoid precipitating diabetes
ANSWER: B
Rationale:
The association between statin use and new-onset diabetes mellitus is well established and recognized in FDA labeling for all statins. Meta-analyses of major statin trials — including the JUPITER trial (rosuvastatin vs. placebo), WOSCOPS, and a landmark 2010 Lancet meta-analysis by Sattar et al. — demonstrate a modest but statistically significant increase in diabetes incidence, approximately 9–13% relative risk increase with statin use. The risk is greatest in patients who already have predisposing factors: impaired fasting glucose, metabolic syndrome, obesity, and elevated baseline HbA1c. The proposed mechanisms include impaired insulin secretion via reduced isoprenylation of small GTPases in pancreatic beta cells, reduced GLUT4 translocation in skeletal muscle impairing peripheral glucose uptake, and reduced adiponectin signaling. Critically, the absolute cardiovascular benefit of statin therapy in patients at elevated cardiovascular risk — prevention of myocardial infarction, stroke, and cardiovascular death — substantially exceeds the absolute risk of precipitating diabetes, particularly in patients who are already on the trajectory toward diabetes (as this patient was, with impaired fasting glucose at baseline). The correct management is to continue statin therapy and address the new diabetes diagnosis with appropriate glucose-lowering intervention.
Option A: Option C: Option D: Option E:
Option A: Option A is incorrect because direct pancreatic beta-cell cytotoxicity is not the established primary mechanism; the effects are multifactorial (insulin secretion impairment, peripheral insulin resistance via GLUT4 and GTPase mechanisms), and the diabetes is generally not fully reversible upon statin discontinuation — it typically represents unmasking or acceleration of underlying insulin resistance in predisposed individuals.
Option C: Option C is incorrect because the association has been confirmed in randomized controlled trials — most definitively the JUPITER trial, which was placebo-controlled — eliminating confounding as the explanation; a causal mechanism has been proposed and is biologically plausible, though not fully elucidated.
Option D: Option D is incorrect because statin-induced diabetes is a class effect observed with both lipophilic and hydrophilic statins, including rosuvastatin (a hydrophilic statin), as demonstrated in JUPITER; the GLUT4 downregulation mechanism is not exclusive to lipophilic statins, and switching statins does not eliminate diabetogenic risk.
Option E: Option E is incorrect because while higher-intensity statins carry a modestly greater absolute diabetogenic risk than lower-intensity statins, withholding high-intensity therapy from a patient who needs it for cardiovascular risk reduction is not guideline-supported; the ACC/AHA guidelines explicitly acknowledge the diabetes risk and recommend continued statin therapy with glucose monitoring, not statin downgrading.
5. A 64-year-old man with mixed dyslipidemia (LDL-C 142 mg/dL, triglycerides 410 mg/dL, HDL-C 31 mg/dL) is on simvastatin 20 mg daily. His physician wishes to add a fibrate to address his hypertriglyceridemia and low HDL-C. Which of the following best explains why gemfibrozil is specifically avoided in combination with statins, while fenofibrate is considered the preferred fibrate for co-administration?
A) Gemfibrozil is a potent CYP3A4 inhibitor that dramatically increases simvastatin plasma concentrations by blocking its hepatic first-pass metabolism, while fenofibrate does not inhibit CYP3A4 and therefore does not alter simvastatin exposure
B) Gemfibrozil displaces statins from plasma protein binding sites, causing a transient spike in free statin concentration that overwhelms hepatic uptake capacity and delivers excess drug to skeletal muscle, while fenofibrate does not affect protein binding
C) Gemfibrozil inhibits UGT1A3-mediated glucuronidation of statin lactone forms, trapping statins in their active acid form and preventing biliary excretion, while fenofibrate undergoes amide hydrolysis and does not interfere with statin glucuronidation
D) Gemfibrozil and its glucuronide metabolite potently inhibit OATP1B1-mediated hepatic uptake of statins and also inhibit CYP2C8, reducing statin clearance and increasing systemic and muscle exposure; fenofibrate does not meaningfully inhibit OATP1B1 or CYP2C8 and is the safer co-administration choice
E) Gemfibrozil activates PPAR-alpha more potently than fenofibrate, producing greater upregulation of lipoprotein lipase and a larger triglyceride-lowering effect that paradoxically increases skeletal muscle fatty acid flux and myopathy risk independent of statin pharmacokinetics
ANSWER: D
Rationale:
The pharmacokinetic basis for avoiding gemfibrozil with statins is well established and mechanistically distinct from fenofibrate. Gemfibrozil and its 1-O-beta-glucuronide metabolite are potent inhibitors of OATP1B1 (organic anion transporting polypeptide 1B1), the hepatic uptake transporter responsible for delivering statins from portal blood into hepatocytes. When OATP1B1 is inhibited, hepatic first-pass extraction of statins is reduced, systemic statin concentrations rise, and greater statin exposure reaches skeletal muscle — the primary site of myotoxicity. In addition, gemfibrozil inhibits CYP2C8, which is involved in the metabolism of cerivastatin and contributes to the metabolism of other statins. The combination of OATP1B1 inhibition and CYP2C8 inhibition produces a substantial pharmacokinetic interaction: gemfibrozil increases simvastatin acid AUC approximately 1.9-fold and increases cerivastatin AUC up to 5.6-fold (a factor that contributed to cerivastatin's market withdrawal). Fenofibrate does not meaningfully inhibit OATP1B1 or CYP2C8 and has not been associated with clinically significant pharmacokinetic statin interactions in clinical studies, making it the preferred fibrate for combination therapy when both a statin and a fibrate are indicated.
Option A: Option B: Option C: Option E:
Option A: Option A is incorrect because gemfibrozil is not a CYP3A4 inhibitor; simvastatin is primarily metabolized by CYP3A4, but gemfibrozil does not inhibit this enzyme; the mechanism of interaction is OATP1B1 and CYP2C8 inhibition, not CYP3A4 inhibition.
Option B: Option B is incorrect because protein displacement is not the established mechanism; while both fibrates and statins are highly protein bound, clinically significant protein displacement interactions are rarely the primary driver of drug interactions with modern agents, and this mechanism has not been identified as responsible for the gemfibrozil-statin myopathy signal.
Option C: Option C is incorrect because while gemfibrozil does inhibit some UGT-mediated glucuronidation pathways, the predominant and pharmacokinetically most significant mechanism of the gemfibrozil-statin interaction is OATP1B1 transporter inhibition, not prevention of biliary excretion via UGT inhibition.
Option E: Option E is incorrect because the gemfibrozil-statin myopathy interaction is pharmacokinetic in origin — increased statin systemic exposure due to reduced hepatic clearance — not a pharmacodynamic effect of PPAR-alpha activation or fatty acid flux; the myopathy risk is not attributable to fibrate-induced changes in muscle metabolism independent of elevated statin concentrations.
6. A 67-year-old woman with established atherosclerotic cardiovascular disease (ASCVD) experienced myalgia and mild CK elevation (3× ULN) on atorvastatin 40 mg daily. The statin was held, symptoms resolved fully within three weeks, and CK normalized. She requires high-intensity statin therapy per guidelines but is apprehensive about rechallenge. Which of the following rechallenge strategies is most consistent with current expert guidance for managing statin intolerance in a patient who requires therapy?
A) Rechallenge with rosuvastatin 5–10 mg every other day (alternate-day dosing), exploiting rosuvastatin's long half-life to achieve meaningful LDL-C reduction while minimizing peak muscle drug exposure, with gradual up-titration as tolerated
B) Rechallenge with the same atorvastatin 40 mg dose after a six-month washout period, as the prior reaction was likely a nocebo effect and the extended washout eliminates residual sensitization
C) Permanently avoid all statin therapy and transition directly to maximum-dose ezetimibe plus a PCSK9 inhibitor, as any prior statin intolerance episode constitutes a contraindication to further statin rechallenge
D) Rechallenge with fluvastatin XL 80 mg daily, as extended-release formulations bypass the peak concentration spike responsible for myopathy and are equally effective to rosuvastatin at high intensity
E) Rechallenge with pitavastatin 4 mg daily and add coenzyme Q10 200 mg daily concurrently, as clinical trials confirm that CoQ10 supplementation prevents recurrence of myopathy during statin rechallenge
ANSWER: A
Rationale:
Statin intolerance — defined as the inability to tolerate statin therapy at doses required to achieve guideline-recommended LDL-C reduction — affects a clinically significant subset of patients, and rechallenge strategies are essential for patients with established ASCVD who cannot safely forgo lipid-lowering therapy. Alternate-day dosing with rosuvastatin exploits its pharmacokinetic properties: rosuvastatin has a half-life of approximately 19 hours and a prolonged pharmacodynamic duration of HMG-CoA reductase inhibition that extends beyond its plasma half-life, allowing meaningful LDL-C reduction with less frequent dosing. By dosing every other day, peak plasma concentrations — which correlate with myopathy risk — are reduced while retaining much of the LDL-C lowering efficacy. Studies and expert consensus (including the ACC/AHA Cholesterol Guidelines and the National Lipid Association SAMS Expert Panel) support alternate-day rosuvastatin as a validated rechallenge strategy in statin-intolerant patients. Gradual up-titration (starting at 5 mg every other day and increasing as tolerated) is recommended. This approach is preferred over permanent statin avoidance in high-risk patients, as even partial LDL-C reduction from low-dose alternate-day statin therapy confers meaningful cardiovascular risk reduction.
Option B: Option C: Option D: Option E:
Option B: Option B is incorrect because rechallenging at the same dose that caused the reaction (atorvastatin 40 mg daily) is not the recommended approach; rechallenge should begin at a lower dose, often with a different statin, particularly one with a more favorable tolerability profile; a six-month washout is also not supported as a rechallenge prerequisite.
Option C: Option C is incorrect because a single intolerance episode on one statin does not constitute a contraindication to all further statin therapy; guidelines recommend systematic rechallenge with a different statin or dosing strategy before concluding true statin intolerance; PCSK9 inhibitors are appropriate adjuncts or alternatives only after genuine rechallenge attempts have failed.
Option D: Option D is incorrect because fluvastatin XL 80 mg, while better tolerated than some statins, does not achieve high-intensity LDL-C reduction (defined as >50% LDL-C lowering) and is classified as moderate-intensity therapy; it is not equivalent to rosuvastatin at high intensity and would not meet the guideline requirement for high-intensity statin therapy in a patient with established ASCVD.
Option E: Option E is incorrect because clinical trials of coenzyme Q10 supplementation in statin-associated myopathy — including randomized controlled trials — have not demonstrated a consistent benefit in preventing myopathy recurrence; CoQ10 is not recommended by ACC/AHA or NLA guidelines as a co-intervention to enable statin rechallenge.
7. A 71-year-old man with a history of acute myocardial infarction two years ago is on maximally tolerated simvastatin 40 mg daily (he cannot tolerate higher doses due to myalgia). His LDL-C remains at 74 mg/dL on statin monotherapy. His cardiologist considers adding ezetimibe. Which of the following best describes the pharmacological basis and clinical evidence supporting ezetimibe addition in this patient?
A) Ezetimibe inhibits hepatic HMG-CoA reductase through a distinct allosteric site, providing additive LDL-C reduction by a complementary mechanism, and the SHARP trial demonstrated a 25% relative reduction in major cardiovascular events when added to statin therapy in patients post-ACS
B) Ezetimibe inhibits intestinal cholesterol absorption by blocking the NPC1L1 transporter, producing a reflex upregulation of hepatic LDL receptors that amplifies statin-mediated LDL-C lowering; however, clinical outcomes data supporting cardiovascular event reduction with ezetimibe addition are limited to chronic kidney disease populations only
C) Ezetimibe inhibits the NPC1L1 (Niemann-Pick C1-Like 1) transporter in the intestinal brush border, reducing cholesterol absorption and complementing statin-mediated reduction in hepatic cholesterol synthesis; the IMPROVE-IT trial demonstrated that simvastatin plus ezetimibe reduced major cardiovascular events compared to simvastatin alone in post-ACS patients, validating the LDL-C lowering hypothesis with a non-statin agent
D) Ezetimibe reduces LDL-C by inhibiting bile acid reabsorption in the terminal ileum, increasing fecal cholesterol excretion; its addition to statin therapy is supported by the IMPROVE-IT trial, which showed a 25% relative risk reduction in cardiovascular events in stable coronary artery disease patients
E) Ezetimibe is a prodrug activated by intestinal esterases to its active glucuronide form, which then inhibits pancreatic cholesterol esterase, reducing dietary cholesterol uptake; its combination with statins is supported by outcomes data from the SHARP trial in post-ACS patients with normal renal function
ANSWER: C
Rationale:
Ezetimibe selectively inhibits the NPC1L1 transporter located on the luminal surface of small intestinal enterocytes. NPC1L1 is the primary transporter responsible for cholesterol absorption from the intestinal lumen; its inhibition reduces the delivery of dietary and biliary cholesterol to the liver. With less cholesterol arriving from the gut, hepatic cholesterol stores fall, triggering upregulation of hepatic LDL receptors via the SREBP-2 pathway — the same pathway activated by statin-mediated HMG-CoA reductase inhibition. This complementary mechanism means ezetimibe and statins work synergistically: statins reduce intrahepatic cholesterol synthesis while ezetimibe reduces exogenous cholesterol delivery, both converging on increased LDL receptor expression and enhanced LDL-C clearance from plasma. The IMPROVE-IT trial (Cannon et al., NEJM 2015) enrolled 18,144 patients stabilized after an acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. After a median follow-up of six years, the combination arm achieved a lower LDL-C (53.7 vs. 69.5 mg/dL) and a statistically significant 6.4% relative reduction (absolute risk reduction 2%) in the primary composite cardiovascular endpoint. IMPROVE-IT was the first trial to demonstrate cardiovascular benefit with a non-statin lipid-lowering agent added to background statin therapy, directly validating the LDL-C hypothesis.
Option A: Option B: Option B correctly identifies the NPC1L1 mechanism and the reflex LDL receptor upregulation but incorrectly states that outcomes data are limited to CKD populations; IMPROVE-IT — a landmark trial in post-ACS patients — provides the primary outcomes evidence supporting ezetimibe addition in the cardiovascular secondary prevention population.
Option D: Option E:
Option A: Option A is incorrect on two counts: ezetimibe does not inhibit HMG-CoA reductase (its mechanism is intestinal NPC1L1 inhibition), and the relevant outcomes trial for post-ACS patients is IMPROVE-IT, not SHARP; SHARP enrolled patients with chronic kidney disease and demonstrated benefit of simvastatin/ezetimibe in that population, not specifically post-ACS patients.
Option D: Option D is incorrect because ezetimibe does not inhibit bile acid reabsorption — that is the mechanism of bile acid sequestrants (cholestyramine, colesevelam); ezetimibe specifically inhibits cholesterol absorption via NPC1L1; additionally, IMPROVE-IT enrolled post-ACS patients (not stable CAD), and the relative risk reduction was approximately 6.4%, not 25%.
Option E: Option E is incorrect because ezetimibe is not activated by intestinal esterases to inhibit pancreatic cholesterol esterase; it is absorbed intact and undergoes glucuronidation in the intestinal wall and liver to form ezetimibe glucuronide (the active enterohepatic-recycled form); its mechanism is NPC1L1 inhibition at the brush border, not pancreatic enzyme inhibition.
8. A 68-year-old man with stage 4 chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] 22 mL/min/1.73 m²), type 2 diabetes, and hypertension requires statin therapy for cardiovascular risk reduction. He is not on dialysis. Which of the following statin choices and dosing considerations is most appropriate for this patient?
A) Atorvastatin 80 mg daily is contraindicated in stage 4 CKD because atorvastatin undergoes predominant renal elimination and accumulates to toxic concentrations as eGFR falls below 30 mL/min/1.73 m²
B) Atorvastatin or fluvastatin are preferred in advanced CKD because they are eliminated predominantly via hepatic/biliary routes with minimal renal excretion, and dose adjustment is generally not required based on renal function alone; rosuvastatin requires dose capping at 10 mg daily in severe renal impairment
C) Simvastatin 40 mg daily is the preferred agent in stage 4 CKD because its hydrophilic profile reduces systemic accumulation, and the SHARP trial specifically validated simvastatin monotherapy (without ezetimibe) as the standard of care in non-dialysis CKD
D) All statins are equally safe in stage 4 CKD provided the dose is halved from the standard maximum; no individual statin has a pharmacokinetic advantage over others in renal impairment because statin elimination is uniformly hepatic across the class
E) Pitavastatin is contraindicated in eGFR below 30 mL/min/1.73 m² due to accumulation of its lactone form, which is renally cleared and produces a dose-dependent nephrotoxic effect that accelerates CKD progression
ANSWER: B
Rationale:
Statin selection in advanced CKD requires attention to elimination pathways, because statins that rely significantly on renal excretion will accumulate as GFR declines, increasing systemic exposure and myopathy risk. Atorvastatin and fluvastatin are the statins with the most favorable pharmacokinetic profile in renal impairment: both are eliminated almost entirely via hepatic metabolism and biliary excretion, with less than 2% of atorvastatin and less than 6% of fluvastatin recovered unchanged in urine. Consequently, their plasma concentrations are not meaningfully affected by renal function, and the FDA label for atorvastatin does not require dose adjustment based on renal impairment. Rosuvastatin, by contrast, has approximately 10% renal elimination — a greater proportion than most statins — and the FDA label recommends a maximum dose of 10 mg daily in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) not on hemodialysis. Simvastatin and pravastatin have intermediate renal components and may also require dose caution in severe CKD. The SHARP trial (Study of Heart and Renal Protection) demonstrated cardiovascular benefit of simvastatin 20 mg plus ezetimibe 10 mg (not simvastatin monotherapy) in patients with CKD, including those on dialysis.
Option A: Option C: Option D: Option E:
Option A: Option A is incorrect because atorvastatin is not predominantly renally eliminated; it undergoes extensive hepatic CYP3A4 metabolism and biliary excretion, and its plasma concentrations are not significantly affected by renal impairment; it is one of the preferred statins precisely because it does not require renal dose adjustment.
Option C: Option C is incorrect on two counts: simvastatin is not specifically preferred over other statins in stage 4 CKD on pharmacokinetic grounds (its renal excretion is intermediate), and the SHARP trial used the combination of simvastatin 20 mg plus ezetimibe 10 mg — not simvastatin monotherapy — as the active treatment arm.
Option D: Option D is incorrect because statins are not uniformly hepatically eliminated; rosuvastatin has meaningful renal excretion (approximately 10%) and requires dose capping in severe renal impairment; the claim that all statins are equivalent in renal impairment is pharmacokinetically inaccurate.
Option E: Option E is incorrect because pitavastatin is not contraindicated in eGFR below 30 mL/min/1.73 m² due to nephrotoxic lactone accumulation; pitavastatin is predominantly hepatically eliminated via glucuronidation and biliary excretion with minimal renal clearance; it is generally considered safe in CKD and does not carry an FDA contraindication for renal impairment in the non-dialysis CKD population.
9. A 55-year-old woman on atorvastatin 40 mg daily for two years has routine liver function tests checked. She is asymptomatic and denies alcohol use, new medications, or symptoms of liver disease. Her alanine aminotransferase (ALT) is 68 U/L (upper limit of normal 35 U/L; 1.9× ULN) and aspartate aminotransferase (AST) is 52 U/L (1.5× ULN). Which of the following most accurately reflects current guidance on statin-associated transaminase elevation?
A) Any transaminase elevation above the upper limit of normal on statin therapy requires immediate drug discontinuation and hepatology referral, as statin-induced hepatotoxicity carries a risk of acute liver failure that necessitates a zero-tolerance threshold
B) Transaminase elevations up to 3× ULN are expected in all patients on high-dose statin therapy and do not require any monitoring or follow-up, as they reflect a benign pharmacological effect of HMG-CoA reductase inhibition on hepatic cholesterol metabolism
C) Statin therapy should be immediately discontinued and the patient evaluated for non-alcoholic fatty liver disease (NAFLD), as any statin-associated ALT elevation is most likely caused by worsening of underlying hepatic steatosis rather than direct drug hepatotoxicity
D) The patient should be switched from atorvastatin to pravastatin, as pravastatin is the only statin with an FDA indication for use in patients with hepatic impairment and does not cause transaminase elevation at any dose
E) Mild transaminase elevations below 3× ULN on statin therapy are generally not an indication to discontinue the drug; the current recommendation is to recheck liver tests in four to six weeks, investigate alternative causes of elevation, and discontinue statin therapy only if ALT exceeds 3× ULN persistently or symptoms of hepatotoxicity develop
ANSWER: E
Rationale:
Statin-associated transaminase elevations are common, typically mild, often transient, and rarely indicative of serious hepatotoxicity. The FDA updated statin labeling in 2012 to remove the requirement for routine periodic liver function test monitoring, reflecting the recognition that mild, asymptomatic transaminase elevations do not predict clinically significant liver injury and that true statin-induced serious hepatotoxicity (acute liver failure) is exceedingly rare — estimated at approximately 1 case per million patient-years of statin use. The threshold that warrants clinical action is persistent elevation of ALT or AST above 3× ULN, particularly if accompanied by symptoms (jaundice, right upper quadrant pain, fatigue) or rising bilirubin. For the patient in this question, with ALT at 1.9× ULN and AST at 1.5× ULN and no symptoms, the appropriate response is to recheck liver tests in four to six weeks, investigate alternative causes (alcohol, other hepatotoxic medications, viral hepatitis, NAFLD, thyroid disease), and continue the statin unless levels rise above 3× ULN or symptoms emerge. Withholding an effective statin from a patient with established cardiovascular risk based on a sub-3× ULN elevation in an asymptomatic patient is not supported by current ACC/AHA or FDA guidance.
Option A: Option B: Option C: Option D:
Option A: Option A is incorrect because it applies a zero-tolerance threshold not supported by any current guideline; mild sub-3× ULN transaminase elevations in asymptomatic patients do not require discontinuation; true statin-induced acute liver failure is exceedingly rare and is not predicted by mild enzyme elevations alone.
Option B: Option B is incorrect because while mild transaminase elevations are common and often benign on statin therapy, they are not "expected in all patients," do not require zero monitoring, and the statement that they reflect a benign pharmacological effect of HMG-CoA reductase inhibition is an oversimplification; persistent elevations above 3× ULN do require action, and alternative causes should always be investigated.
Option C: Option C is incorrect because the instruction to immediately discontinue the statin is not appropriate for a 1.9× ULN asymptomatic elevation; additionally, statins are generally safe and may even be hepatoprotective in NAFLD — they are not contraindicated in hepatic steatosis, and their use in patients with NAFLD is specifically supported by hepatology guidelines in the absence of decompensated cirrhosis.
Option D: Option D is incorrect because pravastatin does not carry an FDA indication for use in hepatic impairment as a preferred or unique agent, and no statin is entirely free of transaminase elevation potential; the claim that pravastatin does not cause transaminase elevation at any dose is inaccurate.
10. A 62-year-old woman with hypercholesterolemia and a two-year history of well-controlled hypothyroidism on levothyroxine presents with new-onset proximal muscle aching and fatigue two months after her levothyroxine dose was reduced by her primary care physician due to a low-normal TSH. Her CK is 2,100 U/L (10.5× ULN). She takes simvastatin 20 mg daily. Which of the following best explains the relationship between her thyroid status and statin-associated myopathy risk?
A) Hypothyroidism directly inhibits CYP3A4 hepatic enzyme activity, reducing simvastatin metabolism and increasing systemic statin exposure to myotoxic concentrations, an effect that is reversed upon achievement of euthyroid status
B) Levothyroxine dose reduction caused hyperthyroidism, which increases skeletal muscle catabolism and sensitizes myocytes to statin-mediated mitochondrial injury, compounding myopathy risk through a pharmacodynamic interaction
C) Hypothyroidism increases plasma fibrinogen and von Willebrand factor concentrations, impairing skeletal muscle microcirculation and causing ischemic myopathy that is misattributed to statins but is in fact entirely independent of statin pharmacology
D) Hypothyroidism independently causes myopathy and elevated CK through impaired muscle energy metabolism and reduced mitochondrial oxidative capacity; it also reduces statin clearance by decreasing hepatic metabolic enzyme activity, increasing statin exposure; the combination substantially amplifies myopathy risk and mandates reassessment of thyroid status before attributing elevated CK solely to the statin
E) Reduced levothyroxine dose caused redistribution of simvastatin from hepatocytes to skeletal muscle by downregulating OATP1B1 expression, increasing myocyte statin exposure independent of any change in plasma statin concentration
ANSWER: D
Rationale:
Hypothyroidism is a well-recognized predisposing condition for statin-associated myopathy and is specifically listed in statin prescribing information as a risk factor. The relationship operates through at least two independent and additive mechanisms. First, hypothyroidism itself causes a myopathy characterized by proximal muscle weakness, elevated CK, and myalgia — through impaired muscle energy metabolism, reduced mitochondrial oxidative phosphorylation efficiency, and abnormal glycogen and lipid accumulation in muscle tissue. CK elevations in untreated or undertreated hypothyroidism can reach 10× ULN or higher without any statin contribution. Second, hypothyroidism reduces hepatic metabolic enzyme activity — including CYP enzymes relevant to statin metabolism — which impairs statin clearance and increases systemic statin exposure, compounding myotoxic risk. In this patient, the levothyroxine dose reduction has led to an undertreated hypothyroid state that is likely contributing to her elevated CK both directly (hypothyroid myopathy) and indirectly (reduced statin clearance). The correct management approach is to reassess and optimize thyroid hormone replacement, hold the statin until thyroid status is normalized and CK rechecked, and then reassess whether statin-associated myopathy remains a concern once the confounding hypothyroid state is resolved.
Option A: Option B: Option B is factually incorrect in its premise; reducing levothyroxine dose causes worsening hypothyroidism, not hyperthyroidism; hyperthyroidism does increase muscle catabolism, but that is the opposite of what has occurred with the dose reduction described in the stem.
Option C: Option E:
Option A: Option A is incorrect in its mechanistic characterization; while hypothyroidism does reduce hepatic metabolic activity broadly, it is not specifically a CYP3A4 inhibitor in the pharmacological sense; more importantly, the answer omits the direct myopathic effect of hypothyroidism on skeletal muscle, which is the primary and most clinically important mechanism in this scenario.
Option C: Option C is incorrect because the proposed mechanism — fibrinogen and von Willebrand factor-mediated ischemic myopathy — is not an established cause of hypothyroid or statin myopathy; the myopathy in this scenario is metabolic and pharmacokinetic in origin, not microvascular-ischemic, and the claim that it is entirely independent of statins is incorrect.
Option E: Option E is incorrect because downregulation of OATP1B1 by hypothyroidism is not an established mechanism for redistributing statin from hepatocytes to skeletal muscle; the relevant pharmacokinetic effect of hypothyroidism is reduced hepatic enzyme-mediated clearance increasing systemic plasma concentrations, not transporter-mediated redistribution to muscle.
11. A 74-year-old man has been taking simvastatin 80 mg daily for nine years without myopathy or significant adverse effects. His LDL-C is well controlled at 58 mg/dL. He is now being seen by a new physician who reviews his medication list. Which of the following most accurately reflects the current regulatory and clinical guidance regarding his simvastatin 80 mg regimen?
A) The FDA issued a safety communication in 2011 restricting the initiation of simvastatin 80 mg in new patients due to an unacceptably high risk of myopathy and rhabdomyolysis at this dose; however, patients who have been on simvastatin 80 mg for 12 or more months without muscle toxicity may continue at this dose, as they have demonstrated tolerance; initiating simvastatin 80 mg in any new patient is prohibited
B) Simvastatin 80 mg is FDA-approved and unrestricted for all patients requiring high-intensity statin therapy; the 2011 FDA communication applied only to patients also taking CYP3A4 inhibitors and was rescinded after the SEARCH trial data were reanalyzed
C) Simvastatin 80 mg should be immediately discontinued in this patient and replaced with a high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg), regardless of his nine-year tolerance history, because continued exposure to simvastatin 80 mg carries cumulative myopathy risk that increases nonlinearly with duration of use
D) The FDA 2011 restriction applies to patients over 65 years of age only, as the myopathy risk from simvastatin 80 mg is age-dependent; patients under 65 without muscle symptoms may continue or initiate simvastatin 80 mg without restriction
E) Simvastatin 80 mg is restricted only when co-administered with fibrates or niacin; this patient's regimen is unrestricted provided he is not taking lipid-modifying combination therapy, and his new physician may continue the current regimen without modification
ANSWER: A
Rationale:
In June 2011, the FDA issued a Drug Safety Communication restricting the use of simvastatin 80 mg based on data from the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial and post-marketing surveillance demonstrating that simvastatin 80 mg carries a substantially higher risk of myopathy and rhabdomyolysis than lower doses or other high-intensity statins. The SEARCH trial documented a 0.9% incidence of confirmed myopathy (including rhabdomyolysis) with simvastatin 80 mg over approximately 6.7 years, compared to 0.03% with simvastatin 20 mg — a 30-fold difference. The 2011 FDA restriction prohibits initiation of simvastatin 80 mg in any new patient. However, the FDA explicitly stated that patients who have already been taking simvastatin 80 mg for 12 months or more without evidence of myopathy may continue at that dose, on the rationale that sustained tolerability over that period is a meaningful predictor of continued tolerance. This patient — nine years on the drug without muscle toxicity — falls squarely within the "established tolerator" exception and may continue. The new physician should document this review and remain vigilant for new interacting medications or clinical changes that would elevate myopathy risk.
Option B: Option C: Option D: Option E:
Option B: Option B is incorrect because the 2011 FDA restriction was not limited to patients on CYP3A4 inhibitors and was not rescinded; it remains in effect and prohibits new initiation of simvastatin 80 mg regardless of concurrent medications; the restriction applies to new prescriptions, not a specific drug interaction scenario.
Option C: Option C is incorrect because the FDA 2011 guidance does not mandate discontinuation in established tolerators; patients who have been on simvastatin 80 mg for 12 or more months without muscle toxicity are explicitly permitted to continue; there is no evidence that myopathy risk increases nonlinearly with duration of use among tolerators, and discontinuing an effective, well-tolerated regimen is not required.
Option D: Option D is incorrect because the FDA restriction is not age-dependent; it applies to all patients regardless of age — simvastatin 80 mg may not be initiated in any new patient, and the age of the patient is not a modifying criterion in the 2011 FDA communication.
Option E: Option E is incorrect because the restriction is not confined to combination therapy with fibrates or niacin; while those combinations carry additional interaction-based myopathy risk and are separately addressed in the prescribing information, the simvastatin 80 mg initiation restriction is absolute and applies regardless of concurrent lipid-modifying agents.
12. A 70-year-old man with persistent atrial fibrillation is started on amiodarone 200 mg daily for rhythm control. His current medications include simvastatin 40 mg daily, which has been well tolerated for four years. Three months after amiodarone initiation he develops proximal muscle weakness and his CK is 4,800 U/L. Which of the following best explains the pharmacokinetic basis of this interaction?
A) Amiodarone activates PXR (pregnane X receptor), inducing CYP3A4 and increasing simvastatin metabolism to its inactive hydroxylated metabolite, paradoxically reducing lipid-lowering efficacy and causing a compensatory increase in muscle cholesterol turnover that produces myopathy
B) Amiodarone inhibits P-glycoprotein in the intestinal wall, markedly increasing simvastatin oral bioavailability by reducing efflux-mediated first-pass intestinal extrusion, raising plasma simvastatin concentrations to myotoxic levels
C) Amiodarone and its active metabolite desethylamiodarone are potent inhibitors of CYP3A4, the primary enzyme responsible for simvastatin metabolism; co-administration markedly reduces simvastatin first-pass and systemic metabolism, increasing simvastatin acid AUC and systemic exposure to myotoxic concentrations
D) Amiodarone inhibits OATP1B1-mediated hepatic uptake of simvastatin, reducing hepatic first-pass extraction and diverting simvastatin to systemic circulation and skeletal muscle, producing a transporter-mediated interaction analogous to the gemfibrozil-statin interaction
E) Amiodarone chelates divalent cations in the intestinal lumen, reducing simvastatin solubility and paradoxically increasing its mucosal permeability through a passive diffusion mechanism that raises peak plasma concentrations and myopathy risk
ANSWER: C
Rationale:
Amiodarone and its principal active metabolite desethylamiodarone are potent inhibitors of CYP3A4, the primary cytochrome P450 enzyme responsible for the hepatic and intestinal metabolism of simvastatin. Simvastatin (a lactone prodrug) is almost entirely dependent on CYP3A4 for its metabolic clearance; when CYP3A4 is inhibited by amiodarone, simvastatin undergoes substantially reduced first-pass metabolism, resulting in markedly increased systemic bioavailability and elevated plasma concentrations of simvastatin acid — the pharmacologically active and myotoxic form. This is the same mechanistic pathway by which other CYP3A4 inhibitors (clarithromycin, itraconazole, cyclosporine) produce myopathy risk with simvastatin. The simvastatin prescribing information specifies a maximum simvastatin dose of 20 mg daily in patients receiving amiodarone, and the FDA 2011 safety update includes amiodarone among the drugs requiring simvastatin dose capping. In this patient, the clinical scenario — new myopathy developing three months after amiodarone initiation with CK at 4,800 U/L — is a classic presentation of CYP3A4-mediated statin toxicity. Management requires holding the statin, allowing CK and symptoms to normalize, then either restarting at a reduced dose (≤20 mg) or switching to a non-CYP3A4-dependent statin such as pravastatin, rosuvastatin, or fluvastatin.
Option A: Option B: Option D: Option E:
Option A: Option A is incorrect because amiodarone is a CYP3A4 inhibitor, not an inducer; it does not activate PXR to induce CYP3A4; induction would reduce simvastatin levels, not increase them, and would not produce myopathy through the mechanism described.
Option B: Option B is incorrect because while amiodarone does have some P-glycoprotein inhibitory activity, this is not the primary or clinically dominant mechanism of the amiodarone-simvastatin interaction; the predominant and pharmacokinetically most significant interaction is CYP3A4 inhibition reducing simvastatin metabolism, not P-glycoprotein-mediated increases in intestinal absorption.
Option D: Option D is incorrect because amiodarone's primary interaction with simvastatin is via CYP3A4 inhibition, not OATP1B1 transporter inhibition; the OATP1B1 mechanism is the basis of the gemfibrozil-statin interaction, not the amiodarone-statin interaction; conflating these two distinct mechanisms is a common pharmacokinetic error.
Option E: Option E is incorrect because amiodarone does not chelate divalent cations in the intestinal lumen or interact with simvastatin through a solubility-permeability mechanism; this distractor describes a mechanism with no pharmacological basis for the amiodarone-simvastatin interaction.
13. An 84-year-old woman with a 10-year history of statin use for primary prevention presents with her daughter for a medication review. She has no history of cardiovascular events. Her current problems include moderate dementia, stage 3 CKD (eGFR 42 mL/min/1.73 m²), recurrent falls, polypharmacy (11 medications), and a recent 8 lb unintentional weight loss. She takes atorvastatin 40 mg daily. Her LDL-C is 88 mg/dL. Which of the following most accurately reflects guideline-concordant benefit-risk assessment for continuing statin therapy in this patient?
A) Statin therapy should be continued unconditionally because the cardiovascular mortality benefit of LDL-C reduction is linear and age-independent; discontinuing a statin in any patient with LDL-C above 70 mg/dL regardless of age, frailty, or life expectancy constitutes a guideline deviation
B) In elderly patients with limited life expectancy, frailty, polypharmacy, and no history of ASCVD, discontinuation of statin therapy for primary prevention is a clinically appropriate and guideline-recognized option; the expected cardiovascular benefit within a shortened time horizon may not outweigh the burdens of polypharmacy, adverse effect risk, and pill burden in a frail patient with dementia
C) Statin therapy should be reduced to a low-intensity dose (atorvastatin 10 mg) rather than discontinued, as all-cause mortality is reduced by any statin dose in patients over 80 and guidelines specify dose reduction rather than discontinuation as the preferred strategy in frailty
D) The statin should be discontinued only if the patient develops an adverse effect; absent active myopathy or hepatotoxicity, continuation of any statin previously tolerated is always guideline-concordant regardless of age or frailty status
E) Statin therapy should be replaced with ezetimibe monotherapy in patients over 80, as ezetimibe lacks the myopathy and drug interaction risks of statins and provides equivalent LDL-C reduction with a better tolerability profile in frail elderly patients
ANSWER: B
Rationale:
The benefit-risk calculus for statin therapy in elderly, frail patients — particularly those in primary prevention — is fundamentally different from younger patients or those with established ASCVD. The cardiovascular benefit of lipid-lowering therapy accrues over years (the number needed to treat for primary prevention benefit is typically calculated over five to ten year horizons), and in a patient with limited life expectancy, dementia, frailty, and no prior cardiovascular events, the time horizon may be insufficient to realize meaningful benefit. The ACC/AHA 2018 Cholesterol Guidelines explicitly acknowledge that in patients over 75 years of age, the benefit-risk assessment becomes less certain, and in those with limited life expectancy, multimorbidity, frailty, or dementia, clinician judgment — informed by patient and caregiver preferences — may appropriately support statin discontinuation, particularly in primary prevention. The ALLHAT-LLT trial and observational data suggest attenuated or uncertain benefit in very elderly primary prevention populations. Furthermore, polypharmacy itself carries significant harm risk in elderly patients (drug-drug interactions, adherence burden, falls risk from side effects), and deprescribing statins in frail elderly primary prevention patients is a recognized and appropriate clinical strategy endorsed by geriatric medicine and palliative care frameworks. A shared decision-making conversation with the patient and her daughter regarding goals of care and life expectancy is the appropriate next step.
Option A: Option C: Option D: Option E:
Option A: Option A is incorrect because the cardiovascular benefit of statin therapy is not linearly age-independent in primary prevention; evidence for benefit in primary prevention patients over 75–80 is limited, and the ACC/AHA guidelines explicitly recognize that benefit-risk reassessment is warranted at this age in primary prevention; an LDL-C threshold is not a sufficient condition to continue therapy regardless of clinical context.
Option C: Option C is incorrect because no guideline specifies that dose reduction is categorically preferred over discontinuation in frail elderly patients; in patients where the primary concern is polypharmacy burden, falls risk, and limited life expectancy, discontinuation may be more appropriate than dose reduction, and there is no established evidence that any statin dose reduces all-cause mortality in all patients over 80 in primary prevention.
Option D: Option D is incorrect because the absence of active adverse effects is not a sufficient justification for unconditional continuation in all patients; benefit-risk reassessment in elderly patients with frailty and limited life expectancy is a distinct and valid clinical indication for considering discontinuation, independent of whether current adverse effects are present.
Option E: Option E is incorrect because ezetimibe monotherapy is not established as equivalent to statin therapy in cardiovascular outcomes and is not guideline-recommended as a replacement for statins in the elderly absent a specific contraindication to statin use; the IMPROVE-IT trial demonstrated ezetimibe benefit as an add-on to statins, not as monotherapy replacement, and there is no outcomes trial supporting ezetimibe monotherapy in frail elderly primary prevention patients.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.